Join the 'Chronic Obstructive Pulmonary Disease' group to help and get support from people like you.

Chronic Obstructive Pulmonary Disease Blog

Related terms: Bronchitis, Chronic, Bronchitis with Airway Obstruction, Chronic Bronchitis, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease, Emphysema, COPD

Certain Sedatives Tied to Breathing Problems in Older COPD Patients

Posted 1 day 21 hours ago by Drugs.com

FRIDAY, April 18, 2014 – A group of widely used sedatives increases the risk of serious breathing problems in older people with the lung condition called chronic obstructive pulmonary disease (COPD), a new study says. Benzodiazepines such as lorazepam (Ativan) or alprazolam (Xanax) are commonly prescribed to treat insomnia and anxiety, the study author noted. For the study, researcher Dr. Nicholas Vozoris examined the medical records of older adults with COPD in the Canadian province of Ontario. Those who had been newly prescribed a benzodiazepine had a 45 percent increased risk of experiencing breathing problems that required outpatient treatment. These patients also had a 92 percent greater risk of needing to go to the emergency room for treatment of pneumonia or COPD, and were more likely to be hospitalized for breathing problems, according to the study published online April 17 in ... Read more

Related support groups: Xanax, Klonopin, Valium, Ativan, Clonazepam, Lorazepam, Alprazolam, Chronic Obstructive Pulmonary Disease, Diazepam, Temazepam, Restoril, Xanax XR, Librium, Oxazepam, Halcion, Serax, Triazolam, Midazolam, Versed, Chlordiazepoxide

Exercise May Curtail COPD Complications

Posted 11 days ago by Drugs.com

WEDNESDAY, April 9, 2014 – Exercise might help reduce the risk of hospital readmission in people with a progressive lung condition called chronic obstructive pulmonary disease (COPD), a new study finds. "Our findings suggest that regular physical activity could buffer the stresses of hospitalization," said study author Huong Nguyen, of the Kaiser Permanente Southern California Department of Research and Evaluation. "Future studies will focus on determining whether we can reduce hospitalizations by improving physical activity in patients with COPD," Nguyen added. COPD refers to a group of diseases, including emphysema and chronic bronchitis, that cause airflow blockage and breathing problems. Fifteen million Americans report they have a COPD diagnosis, according to the U.S. Centers for Disease Control and Prevention. For this study, published April 9 in the Annals of the American ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

COPD May Damage Aging Brain

Posted 18 Mar 2014 by Drugs.com

TUESDAY, March 18, 2014 – Seniors with chronic obstructive pulmonary disease (COPD) have an increased risk of developing mental decline, especially thinking problems without apparent memory loss, a new study suggests. This diminished brain function – called "nonamnestic" mild cognitive impairment – was significantly more common among older adults with COPD than those without the disabling respiratory disorder, according to the study of more than 1,400 adults. "We found that COPD was associated with problems with attention, planning and problem-solving, but not with memory," said study co-author Michelle Mielke, an associate professor with the division of epidemiology at the Mayo Clinic in Rochester, Minn. "This is important, because for one thing COPD is potentially preventable," Mielke said. Also, in order to preserve long-term mental functioning, this finding highlights the need to ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

2-Mile Daily Walk Might Help Fight COPD

Posted 5 Mar 2014 by Drugs.com

WEDNESDAY, March 5, 2014 – Taking daily walks of at least two miles can reduce hospitalizations from severe episodes of a life-threatening breathing disorder, new research suggests. Scientists found that chronic obstructive pulmonary disease (COPD) patients without regular walking regimens had about twice the rate of hospitalizations triggered by the condition compared to those who maintained the highest levels of physical activity. This was defined as walking between roughly two and four miles each day. "Of course, daily walking acts to improve the exercise capacity of these patients," said study author Dr. Cristobal Esteban, a staff member in the respiratory service at Hospital Galdakao-Usansolo, in Spain. "Physical activity is a 'medicine' that will improve your general condition as well as COPD." The study appeared online recently in the journal Respirology. The third-leading cause ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

FDA Approves Anoro Ellipta to Treat COPD

Posted 18 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 18, 2013 – A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. The lung disease makes breathing difficult and worsens over time. "Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD," he added. Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Anoro Ellipta Approved for COPD

Posted 18 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 18, 2013 – Anoro Ellipta (umeclidinium and vilanterol inhalation powder) has been approved by the U.S. Food and Drug Administration for once-daily treatment of chronic obstructive pulmonary disease (COPD). COPD, an umbrella term that includes the lung diseases bronchitis and emphysema, is a progressive condition that interferes with breathing. Symptoms may include chest tightness, chronic cough and overproduction of phlegm. It's the third-leading cause of death in the United States, the FDA said in a news release. Anoro Ellipta, a combination of two approved medications, relaxes the lung airways to help breathing. The drug's safety and effectiveness were evaluated in clinical trials involving more than 2,400 people diagnosed with COPD. The drug's label includes a warning that users have an increased risk of asthma-related death. However, the medication has not been ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

FDA Approves Anoro Ellipta to Treat Chronic Obstructive Pulmonary Disease

Posted 18 Dec 2013 by Drugs.com

December 18, 2013 – The U.S. Food and Drug Administration today approved Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). COPD is a serious lung disease that makes breathing difficult and worsens over time. Symptoms can include chest tightness, chronic cough and excessive phlegm. Cigarette smoking is the leading cause of COPD. According to the National Heart, Lung, and Blood Institute, COPD is the third leading cause of death in the United States. “Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “The availability of new ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute, COPD, Chronic Obstructive Lung Disease, COPD, Maintenance, Chronic Obstructive Airway Disease, COPD, Acute

COPD Tied to Tiny Brain Bleeds, Study Finds

Posted 19 Jul 2013 by Drugs.com

FRIDAY, July 19 – People with the lung condition called chronic obstructive pulmonary disease (COPD) are at increased risk for bleeding in the brain, a new study finds. Researchers looked at 165 people with COPD and 645 people with normal lung function and found that those with COPD were more likely to have what are called cerebral microbleeds. The more severe a patient's breathing problems, the more likely they were to have microbleeds, according to the study, published online July 19 in the American Journal of Respiratory and Critical Care Medicine. Cerebral microbleeds are an indicator of disease in the brain's small blood vessels (cerebral small vessel disease), which is an important cause of age-related mental decline and disability. It was known that people with COPD are at increased risk for large vessel disease, but these new findings "indicate that COPD might affect both large ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Blood Tests May Predict COPD Flare-Ups

Posted 11 Jun 2013 by Drugs.com

TUESDAY, June 11 – People with chronic obstructive pulmonary disease (COPD) who have signs of chronic inflammation in their blood are more likely to have flare-ups of the lung disease than those who do not, a large new study shows. In addition to the slow, steady deterioration in lung function caused by COPD, patients can have sudden, distressing flare-ups. These so-called "exacerbations" are periods of worsening breathing problems that are typically triggered by infections or air pollution. Patients who experience frequent flare-ups decline more quickly than those who do not; they also tend to have worse quality of life and poorer survival rates than those whose conditions are more stable, according to background information in the study. Preventing flare-ups is a major goal of COPD treatment, but these episodes can be difficult to predict. In a study of more than 61,000 people in ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Breo Ellipta Approved for COPD

Posted 24 May 2013 by Drugs.com

FRIDAY, May 10 – Americans with chronic obstructive pulmonary disease (COPD) may have new help in their quest to breathe better, with the approval of Breo Ellipta on Friday. This combination drug has been approved by the Food and Drug Administration to treat COPD, which includes chronic bronchitis or emphysema. COPD is the third-leading cause of death in the U.S. behind heart disease and cancer, with typical symptoms including chronic cough, chest tightness and excess phlegm. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is designed to reduce lung inflammation and to relax muscles that impact the lung airways, the FDA said Friday in a news release. The drug's safety and effectiveness were clinically evaluated in some 7,700 people with COPD. Common side effects included nasal inflammation, upper respiratory infection and headache. Less common but more serious side ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

COPD May Be Over-Diagnosed Among Uninsured

Posted 22 May 2013 by Drugs.com

WEDNESDAY, May 22 – Roughly four in 10 uninsured patients who have been diagnosed with chronic obstructive pulmonary disease (COPD) actually do not have the lung disease, a small new study suggests. At issue: Faulty diagnoses were made based on an evaluation of symptoms, rather than by means of the so-called "gold standard" disease test known as spirometry, which shows how well a patient's lungs are working by measuring the amount of air they can exhale and how long that takes. The study is scheduled for presentation Wednesday at the American Thoracic Society annual meeting in Philadelphia. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal. COPD is a progressive disease that makes it hard to breathe. Symptoms include coughing, wheezing, shortness of breath and chest tightness, according to the U.S. National Heart, Lung, and Blood ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

COPD Patients May Do Fine With Shorter Course of Steroids

Posted 21 May 2013 by Drugs.com

TUESDAY, May 21 – Less is more when it comes to steroid therapy for patients having severe bouts of chronic obstructive pulmonary disease (COPD), according to Swiss investigators. Five days of glucocorticoid treatment with prednisone to treat COPD flare-ups was as good as the standard 14 days, but with fewer chances for adverse side effects, they said. "We wanted to show that a shorter period of treatment was not less effective than 14 days," said lead researcher Dr. Jorg Leuppi, with the department of medicine at the University Hospital of Basel. The shorter course of treatment had the same outcome as the longer course of treatment, the study found. "There is exactly the same time to recovery and exactly the same number of re-exacerbations," Leuppi said. In addition, the shorter course of treatment meant fewer side effects from the drug, such as increased blood pressure and elevated ... Read more

Related support groups: Prednisone, Chronic Obstructive Pulmonary Disease, Prednisolone, Methylprednisolone, Cortisone, Hydrocortisone, Medrol, Triamcinolone, Dexamethasone, Betamethasone, Decadron, Entocort, Budesonide, Solu-Medrol, Cortef, Celestone, Entocort EC, Orapred, Depo-Medrol, Medrol Dosepak

Pain a Common Problem for People With COPD

Posted 21 May 2013 by Drugs.com

TUESDAY, May 21 – Chronic obstructive pulmonary disease (COPD) patients experience a significant amount of pain, new research suggests. Pain levels are nearly on par with the kind of discomfort experienced by many osteoarthritis and rheumatoid arthritis patients, according to the study, which is scheduled for presentation Tuesday at the American Thoracic Society annual meeting in Philadelphia. "Several studies have found high rates of pain medication use among COPD patients, and pain has also been an important determinant of overall health status and quality of life in COPD," study author Melissa Roberts, a senior research associate at the Lovelace Clinic Foundation in Albuquerque, N.M., said in a society news release. The researchers analyzed data on nearly 8,000 COPD patients over the age of 40. Nearly 16,000 other men and women not diagnosed with COPD also were included in the ... Read more

Related support groups: Pain, Chronic Obstructive Pulmonary Disease

Long-Term Use of Antibiotic May Help Those With COPD

Posted 21 May 2013 by Drugs.com

TUESDAY, May 21 – Thousands of Americans, many of them smokers or ex-smokers, suffer from the lung condition known as chronic obstructive pulmonary disease (COPD). Now a new study finds that patients placed on the common antibiotic azithromycin may be able to cut down on hospitalizations due to flare-ups of the disease. "Given that exacerbations of COPD can be life-threatening, prevention of such events is critical," said Victoria Richards, assistant professor of medical science at Quinnipiac University in Hamden, Conn. Use of the antibiotic might also cut down on the need for doctor's office visits and boost patients' quality of life, said Richards, who was not involved in the study. The research was presented Tuesday at the annual meeting of the American Thoracic Society in Philadelphia. COPD is a progressive disease involving bronchitis and emphysema, often tied to smoking, that ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Azithromycin, Zithromax, Zithromax Z-Pak, Zithromax TRI-PAK, Zithromax IV, Zmax

Certain COPD Meds Might Raise Heart Risks, Study Says

Posted 20 May 2013 by Drugs.com

MONDAY, May 20 – Long-acting inhaled medications used by millions of people with chronic obstructive pulmonary disease (COPD) may raise the risk of cardiovascular complications among older patients, a new large Canadian study reveals. The finding centers around patients over age 65 who are prescribed long-acting bronchodilators – either anticholinergics (such as Spiriva) or beta-agonists (such as Serevent). Both medications are commonly used to relieve the shortness of breath that characterizes moderate to severe COPD and to improve lung function. The team found that compared with patients who do not use either medication, those using either of these bronchodilators face a notably higher risk for experiencing a cardiac event, such as heart attack or heart failure. "The bad news is that, although everybody's different, there's a chance that by using these long-acting bronchodilators ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Albuterol, Spiriva, Chronic Obstructive Pulmonary Disease, Maintenance, Ventolin, Epinephrine, Xopenex, ProAir HFA, Ipratropium, Atrovent, Proventil, Chronic Obstructive Pulmonary Disease, Acute, Primatene Mist, Salmeterol, EpiPen, Ventolin HFA, Spiriva HandiHaler, Tiotropium, Alupent, Terbutaline

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute, Alpha-1 Proteinase Inhibitor Deficiency, Respiratory Tract Disease

Related Drug Support Groups

prednisone, Symbicort, montelukast, Daliresp, Bronchial, Bronkometer, Tudorza Pressair, Breo Ellipta, Rayos, view more... guaifenesin/theophylline, isoetharine, Solu-Phyllin GG, Theolate, Theocon, Broncomar GG, Bronkosol, Uni Bronchial, Broncodur, Theophyll-GG, Ed-Bron G, Theo G, Equibron G, Dilor-400, umeclidinium/vilanterol, Dylix, Dilor, fluticasone/vilanterol, aclidinium, dyphylline, roflumilast, Lufyllin, Quibron, Asbron G, Slo-Phyllin GG, budesonide/formoterol, Lufyllin-400, Theomar GG, Neothylline, Glyceryl T